What to know first
Answer-first notes for searchers, readers, and clinician conversations.
What the evidence can and cannot answer
Reduced appetite and gastrointestinal effects can change how much or what a person eats during GLP-1 treatment. The current Wegovy and Zepbound labels list gastrointestinal adverse reactions and warn about acute kidney injury due to volume depletion in the setting of reactions such as nausea, vomiting, or diarrhea. Those product-specific labels do not establish a universal diet, protein target, fluid target, or fiber target.
Lean mass changes need population and timeframe context
In a DXA substudy of 160 SURMOUNT-1 participants with obesity or overweight and measurements at baseline and week 72, both fat mass and lean mass decreased during weight reduction. About one quarter of weight lost was lean mass in the pooled tirzepatide groups and placebo group, but this small substudy was not designed to predict one person's body-composition change or establish effects on strength or physical function.
Protein is a discussion point, not a universal prescription
A 2025 multi-organization joint advisory, checked with its 2026 corrigendum, identifies protein adequacy, resistance activity, and assessment of muscle function or body composition as clinical considerations during obesity treatment with GLP-1 medicines. It is an expert advisory rather than a randomized test of one protein target, and it notes that there is no consensus on the optimal method for determining protein needs.
Hydration, fiber, and gastrointestinal symptoms
Constipation is listed among common adverse reactions in the current Wegovy and Zepbound labels. The labels also connect some acute kidney injury reports to dehydration or volume depletion associated with gastrointestinal reactions. They support taking persistent vomiting, diarrhea, inability to keep fluids down, or dehydration concerns seriously; they do not prove that a fixed amount of water or fiber prevents those outcomes.
What the evidence can and cannot answer
Reduced appetite and gastrointestinal effects can change how much or what a person eats during GLP-1 treatment. The current Wegovy and Zepbound labels list gastrointestinal adverse reactions and warn about acute kidney injury due to volume depletion in the setting of reactions such as nausea, vomiting, or diarrhea. Those product-specific labels do not establish a universal diet, protein target, fluid target, or fiber target.
Lean mass changes need population and timeframe context
In a DXA substudy of 160 SURMOUNT-1 participants with obesity or overweight and measurements at baseline and week 72, both fat mass and lean mass decreased during weight reduction. About one quarter of weight lost was lean mass in the pooled tirzepatide groups and placebo group, but this small substudy was not designed to predict one person's body-composition change or establish effects on strength or physical function.
A 2026 systematic review of 20 randomized trials and 15,782 adults with overweight or obesity found that lean mass contributed to weight lost with incretin therapy and with intensive lifestyle interventions. Results varied across medicines, measurement methods, and interventions, and the review reported moderate heterogeneity; a single percentage should not be applied to every reader.
Protein is a discussion point, not a universal prescription
A 2025 multi-organization joint advisory, checked with its 2026 corrigendum, identifies protein adequacy, resistance activity, and assessment of muscle function or body composition as clinical considerations during obesity treatment with GLP-1 medicines. It is an expert advisory rather than a randomized test of one protein target, and it notes that there is no consensus on the optimal method for determining protein needs.
This guide therefore does not provide individualized targets. Age, kidney function, medical history, baseline intake, treatment effects, and other factors belong in a clinician or registered dietitian conversation.
Hydration, fiber, and gastrointestinal symptoms
Constipation is listed among common adverse reactions in the current Wegovy and Zepbound labels. The labels also connect some acute kidney injury reports to dehydration or volume depletion associated with gastrointestinal reactions. They support taking persistent vomiting, diarrhea, inability to keep fluids down, or dehydration concerns seriously; they do not prove that a fixed amount of water or fiber prevents those outcomes.
The joint advisory discusses fluids and food-based fiber as possible parts of individualized gastrointestinal support, while also noting that higher-fiber foods may aggravate some symptoms at some times. Symptom pattern, comorbidities, medications, and clinician guidance matter more than a one-size-fits-all rule.
What to bring to a clinician or dietitian
Useful observations include changes in appetite and intake, persistent gastrointestinal symptoms, ability to keep fluids down, bowel-pattern changes, fatigue or weakness, and concerns about strength or physical function. These observations can support an individualized assessment; they are not a self-dosing or self-treatment protocol.
Evidence gaps
No universal protein, fluid, or fiber target has been validated for every person using a GLP-1 or related incretin medicine. Trials do not consistently measure diet, muscle strength, physical function, or long-term outcomes after treatment changes, and body-composition substudies represent only subsets of larger trials.
Evidence also does not establish that one nutrition strategy prevents lean-mass loss or gastrointestinal adverse effects across products and populations. These gaps are why the page stays education-only and avoids individualized dietary, supplement, exercise, medication, or dosing instructions.
Sources and further reading
These links are included to make the evidence trail visible. They are not sponsor links and do not replace product-specific medical advice.